Interestingly, in an ongoing clinical trial for CRC patients combining the PD-1 inhibitor nivolumab with the CTLA-4 inhibitor ipilimumab, an improved efficiency was suggested in the combination therapy group [22]. Here, CTLA4 is linked to colorectal carcinoma.